Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience

作者： A.-K. Lalani , H. Li , D. Heng , L. Wood , A. Kalirai

DOI: 10.1093/ANNONC/MDW373.46

关键词: